Homology Medicines, Inc. (0T6G.L)
USD 1.94
(-2.52%)
USD 1.94
(-2.52%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 43.17 Million USD | 264.11% |
| 2022 | 11.85 Million USD | 138.5% |
| 2021 | 4.97 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 12.55 Million USD | 33.55% |
| 2024 Q1 | 9.4 Million USD | -78.23% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 FY | 49.42 Million USD | 316.8% |
| 2023 Q4 | 49.42 Million USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q4 | 11.85 Million USD | 0.0% |
| 2022 FY | 11.85 Million USD | 138.5% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 FY | 4.97 Million USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 92.72% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1304.554% |
| Myriad Genetics, Inc. | 130.9 Million USD | 67.016% |
| Evolus, Inc. | 120.35 Million USD | 64.127% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 96.917% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.421% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 24.237% |
| uniQure N.V. | 130.06 Million USD | 66.804% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 5.509% |
| bluebird bio, Inc. | 224.41 Million USD | 80.761% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -880.827% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.157% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 88.868% |
| Dynavax Technologies Corporation | 252.41 Million USD | 82.895% |
| Editas Medicine, Inc. | 24.37 Million USD | -77.154% |
| FibroGen, Inc. | 89.69 Million USD | 51.865% |
| Geron Corporation | 35.05 Million USD | -23.181% |
| Blueprint Medicines Corporation | 610.96 Million USD | 92.933% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.667% |
| Illumina, Inc. | 1.48 Billion USD | 97.1% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -4217.6% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -26.283% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 83.285% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -16.443% |
| Adicet Bio, Inc. | 17.7 Million USD | -143.891% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 96.188% |
| Insmed Incorporated | 1.19 Billion USD | 96.382% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 55.372% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 97.814% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -83.423% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -30.064% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.463% |
| Waters Corporation | 2.3 Billion USD | 98.127% |
| Zoetis Inc. | 6.56 Billion USD | 99.342% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.862% |
| Biogen Inc. | 7.18 Billion USD | 99.399% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -28.826% |
| Nektar Therapeutics | 112.62 Million USD | 61.664% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -4512.821% |
| Perrigo Company plc | 3.63 Billion USD | 98.811% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 75.753% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 75.151% |
| Verastem, Inc. | 40.08 Million USD | -7.708% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 94.042% |
| Imunon, Inc. | 1.13 Million USD | -3689.719% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -1233.156% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 91.391% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.403% |
| OPKO Health, Inc. | 222.03 Million USD | 80.554% |
| Exelixis, Inc. | 189.94 Million USD | 77.269% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.12% |
| TG Therapeutics, Inc. | 100.11 Million USD | 56.875% |
| Incyte Corporation | 29.16 Million USD | -48.056% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 90.33% |